Logo image of BME

BLACKROCK HEALTH SCIENCES (BME) Stock Price, Quote, News and Overview

NYSE:BME - New York Stock Exchange, Inc. - US09250W1071 - Currency: USD

40.23  -0.23 (-0.57%)

After market: 40.14 -0.09 (-0.22%)

Fundamental Rating

2

Overall BME gets a fundamental rating of 2 out of 10. We evaluated BME against 0 industry peers in the Unkown industry. Both the profitability and financial health of BME have multiple concerns. BME has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

BME had positive earnings in the past year.
In the past year BME had a positive cash flow from operations.
Of the past 5 years BME 4 years were profitable.
In the past 5 years BME reported 4 times negative operating cash flow.
BME Yearly Net Income VS EBIT VS OCF VS FCFBME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

1.2 Ratios

The last Return On Invested Capital (0.26%) for BME is above the 3 year average (0.16%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.75%
ROE 7.89%
ROIC 0.26%
ROA(3y)2.7%
ROA(5y)8.01%
ROE(3y)2.81%
ROE(5y)8.18%
ROIC(3y)0.16%
ROIC(5y)0.12%
BME Yearly ROA, ROE, ROICBME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 5 -5 10 15

1.3 Margins

BME's Profit Margin has declined in the last couple of years.
BME's Operating Margin has improved in the last couple of years.
Industry RankSector Rank
OM 23.94%
PM (TTM) 572.54%
GM 99.56%
OM growth 3Y163.63%
OM growth 5Y10.93%
PM growth 3Y-45.61%
PM growth 5Y-13.18%
GM growth 3YN/A
GM growth 5YN/A
BME Yearly Profit, Operating, Gross MarginsBME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K 1.5K

More info and screens

3

2. Health

2.1 Basic Checks

BME has more shares outstanding than it did 1 year ago.
BME has more shares outstanding than it did 5 years ago.
BME has a better debt/assets ratio than last year.
BME Yearly Shares OutstandingBME Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
BME Yearly Total Debt VS Total AssetsBME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 32.46 indicates that BME is not in any danger for bankruptcy at the moment.
The Debt to FCF ratio of BME is 0.17, which is an excellent value as it means it would take BME, only 0.17 years of fcf income to pay off all of its debts.
A Debt/Equity ratio of 0.00 indicates that BME is not too dependend on debt financing.
Even though the debt/equity ratio score it not favorable for BME, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.17
Altman-Z 32.46
ROIC/WACCN/A
WACCN/A
BME Yearly LT Debt VS Equity VS FCFBME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

BME has a Current Ratio of 0.93. This is a bad value and indicates that BME is not financially healthy enough and could expect problems in meeting its short term obligations.
A Quick Ratio of 0.93 indicates that BME may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.93
Quick Ratio 0.93
BME Yearly Current Assets VS Current LiabilitesBME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 168.30% over the past year.
The Earnings Per Share has been decreasing by -8.84% on average over the past years.
BME shows a small growth in Revenue. In the last year, the Revenue has grown by 6.03%.
The Revenue has been growing by 12.58% on average over the past years. This is quite good.
EPS 1Y (TTM)168.3%
EPS 3Y-40.01%
EPS 5Y-8.84%
EPS Q2Q%-75.22%
Revenue 1Y (TTM)6.03%
Revenue growth 3Y16.07%
Revenue growth 5Y12.58%
Sales Q2Q%-0.86%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BME Yearly Revenue VS EstimatesBME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
BME Yearly EPS VS EstimatesBME Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 28.13 indicates a quite expensive valuation of BME.
When comparing the Price/Earnings ratio of BME to the average of the S&P500 Index (29.63), we can say BME is valued inline with the index average.
Industry RankSector Rank
PE 28.13
Fwd PE N/A
BME Price Earnings VS Forward Price EarningsBME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 36.39
EV/EBITDA N/A
BME Per share dataBME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

5

5. Dividend

5.1 Amount

BME has a Yearly Dividend Yield of 6.19%, which is a nice return.
Compared to an average S&P500 Dividend Yield of 2.27, BME pays a better dividend.
Industry RankSector Rank
Dividend Yield 6.19%

5.2 History

BME has paid a dividend for at least 10 years, which is a reliable track record.
BME has not decreased its dividend in the past 5 years, so it has a somewhat stable track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years9
BME Yearly Dividends per shareBME Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2 2.5

5.3 Sustainability

71.65% of the earnings are spent on dividend by BME. This is not a sustainable payout ratio.
DP71.65%
EPS Next 2YN/A
EPS Next 3YN/A
BME Yearly Income VS Free CF VS DividendBME Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M
BME Dividend Payout.BME Dividend Payout, showing the Payout Ratio.BME Dividend Payout.PayoutRetained Earnings

More info and screens

BLACKROCK HEALTH SCIENCES

NYSE:BME (2/21/2025, 8:04:00 PM)

After market: 40.14 -0.09 (-0.22%)

40.23

-0.23 (-0.57%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners22.44%
Inst Owner Change1.64%
Ins Owners0%
Ins Owner Change0%
Market Cap560.81M
Analysts0
Price TargetN/A
Short Float %0.12%
Short Ratio0.26
Dividend
Industry RankSector Rank
Dividend Yield 6.19%
Yearly Dividend2.52
Dividend Growth(5Y)N/A
DP71.65%
Div Incr Years0
Div Non Decr Years9
Ex-Date02-14 2025-02-14 (0.2621)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 28.13
Fwd PE N/A
P/S 68.14
P/FCF 36.39
P/OCF 36.39
P/B 0.94
P/tB 0.94
EV/EBITDA N/A
EPS(TTM)1.43
EY3.55%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.11
FCFY2.75%
OCF(TTM)1.11
OCFY2.75%
SpS0.59
BVpS42.85
TBVpS42.85
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.75%
ROE 7.89%
ROCE 0.33%
ROIC 0.26%
ROICexc 0.26%
ROICexgc 0.26%
OM 23.94%
PM (TTM) 572.54%
GM 99.56%
FCFM 187.24%
ROA(3y)2.7%
ROA(5y)8.01%
ROE(3y)2.81%
ROE(5y)8.18%
ROIC(3y)0.16%
ROIC(5y)0.12%
ROICexc(3y)0.16%
ROICexc(5y)0.12%
ROICexgc(3y)0.16%
ROICexgc(5y)0.12%
ROCE(3y)0.2%
ROCE(5y)0.15%
ROICexcg growth 3Y198.66%
ROICexcg growth 5Y12.56%
ROICexc growth 3Y198.66%
ROICexc growth 5Y12.56%
OM growth 3Y163.63%
OM growth 5Y10.93%
PM growth 3Y-45.61%
PM growth 5Y-13.18%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.17
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion N/A
Profit Quality 32.7%
Current Ratio 0.93
Quick Ratio 0.93
Altman-Z 32.46
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)168.3%
EPS 3Y-40.01%
EPS 5Y-8.84%
EPS Q2Q%-75.22%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)6.03%
Revenue growth 3Y16.07%
Revenue growth 5Y12.58%
Sales Q2Q%-0.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y222.95%
EBIT growth 3Y205.99%
EBIT growth 5Y24.89%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y502.35%
FCF growth 3YN/A
FCF growth 5Y73.27%
OCF growth 1Y502.35%
OCF growth 3YN/A
OCF growth 5Y73.27%